<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621370</url>
  </required_header>
  <id_info>
    <org_study_id>PrimeRT-2018</org_study_id>
    <nct_id>NCT04621370</nct_id>
  </id_info>
  <brief_title>A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer</brief_title>
  <acronym>PRIME-RT</acronym>
  <official_title>Priming the Tumour MicroEnvironment for Effective Treatment With Immunotherapy in Locally Advanced Rectal Cancer A Phase II Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liz-Anne Lewsley</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Research UK, Glasgow</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRIME-RT is an open label, multi-centre phase II randomised trial with 1:1 allocation between&#xD;
      arm A and arm B. The principal research question is whether the addition of durvalumab to&#xD;
      FOLFOX chemotherapy and radiation treatment (either SCRT or LCRT) in the neoadjuvant setting&#xD;
      for patients with locally advanced rectal cancer (LARC) improves rates of complete response.&#xD;
      The working hypothesis is that the use of radiation and cytotoxic chemotherapy may prime the&#xD;
      tumour immune microenvironment for treatment with immune checkpoint blockade. The main trial&#xD;
      will commence after completion of a safety run-in which will enrol at least three patients&#xD;
      per arm to test the safety and tolerability of the treatment combinations in each.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In rectal cancer, strategies to enhance local treatment responses by expanding neoadjuvant&#xD;
      regimens are sought to enable organ preservation in more patients. The addition of systemic&#xD;
      FOLFOX post long course chemoradiotherapy (LCRT) and post short course radiotherapy (SCRT)&#xD;
      has been reported with encouraging results demonstrating higher rates of complete response&#xD;
      than with radiotherapy based treatment alone. Immunotherapy using PD-1/ PD-L1 inhibition is&#xD;
      recognised to be effective in mismatch repair deficient colorectal cancer (dMMR). Generally,&#xD;
      dMMR tumours are characterised by a higher mutational burden, a higher neoantigen load with&#xD;
      high density T cell infiltrates and increased expression of PD-1/ PD-L1 in the tumour&#xD;
      microenvironment (TME). Mismatch repair proficient (pMMR) colorectal cancer is not thought to&#xD;
      be responsive to immunotherapies partly due to the fact they exhibit low levels of tumour&#xD;
      infiltrating lymphocytes (TILs) and PD-1/PD-L1 within the TME. Attempts to expand the role of&#xD;
      anti-PD-L1 treatment to pMMR CRC is likely to rely on provision of conventional DNA damaging&#xD;
      treatments to increase tumour immunogenicity/ T cell infiltration. At baseline few rectal&#xD;
      tumours (10-20%) demonstrate moderate-high grade CD3+ responses within the TME, but there is&#xD;
      evidence that radiotherapy (e.g. SCRT or LCRT) and systemic chemotherapy (FOLFOX) induce&#xD;
      favourable immune responses. In this phase II trial, the investigators plan to evaluate the&#xD;
      potential treatment efficacy of anti-PD-L1 systemic anticancer treatment, durvalumab,&#xD;
      alongside either SCRT or LCRT with FOLFOX in the gap up to post treatment assessment. This&#xD;
      trial will evaluate rates of complete response in each arm as its primary endpoint in&#xD;
      addition to safety and toxicity as secondary endpoints. It is a translationally rich trial&#xD;
      which involves the collection of biospecimens prior to, during and following treatment in&#xD;
      order to understand the molecular and immunological factors underpinning treatment response.&#xD;
&#xD;
      An initial 6 patient safety run-in (3 patients in each arm) will be performed treating&#xD;
      patients with metastatic disease with a locally advanced rectal cancer in situ or patients&#xD;
      with locally advanced rectal cancer who will never undergo radical surgery due to patient&#xD;
      choice, in order to establish safety and lack of significant local toxicity due to the&#xD;
      combination (for example colo-proctitis). Depending on the toxicity observed in the first 3&#xD;
      evaluable patients in each of the arm, an additional 3 patients may be add to that arm for&#xD;
      the safety run-in cohort. Following an independent safety review and approval by an&#xD;
      Independent Data Monitoring Committee (IDMC), the main trial will commence.&#xD;
&#xD;
      Following the safety run-in, 42 patients with non-metastatic, biopsy confirmed rectal&#xD;
      adenocarcinoma (cT3b+, N+, EMVI+ based on MRI staging or low rectal tumours requiring&#xD;
      abdominoperineal resection) will be recruited to the main trial and randomised to one of two&#xD;
      treatment arms. These patients must have adequate physical fitness and no previous pelvic&#xD;
      radiotherapy or immunotherapy.&#xD;
&#xD;
      Recruitment to the Safety Run-in period is expected to take 6 months (based on 6 patients in&#xD;
      this cohort) with the main trial taking a further 12 months. Recruitment should therefore&#xD;
      take place over a total period of 18 months. If the safety run-in requires more than 6&#xD;
      patients, these timelines will be revised. Patients will be followed up for 36 months from&#xD;
      date of randomisation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 7, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response</measure>
    <time_frame>6 months</time_frame>
    <description>Pathological or clinical complete response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During neo-adjuvant treatment and for up to at least 90 days after the last dose of Investigatinal Medicinal Product (IMP).</time_frame>
    <description>Occurrence of Grade 3-5 treatment-emergent adverse events and treatment-related adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD3+ T cell infiltrate</measure>
    <time_frame>Week 2, week 6 and end of treatment (Week 15-18)</time_frame>
    <description>Presence of a moderate-high grade CD3+ T cell infiltrate on rectal tumour biopsy during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neoadjuvant Rectal (NAR) score</measure>
    <time_frame>Immediately after the surgery</time_frame>
    <description>In patients who do not achieve a clinical complete respose (cCR), the proportion of patients with a Neodjuvant Rectal (NAR) score &lt;8. The NAR score is a pseudo-continuous scale with 24 possible discrete scores ranging from 0-100. A low score was defined as &lt;8, intermediate as 8-16 and high as &gt;16 with corresponding 5 year OS in this patient cohort of 92%, 89% and 68% respectively, showing that higher scores are associated with poorer prognosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI defined tumour regression</measure>
    <time_frame>End of Treatment (Week 15-18)</time_frame>
    <description>Proportion of patients achieving MRI-confirmed near or complete tumour regression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI defined down-staging</measure>
    <time_frame>End of Treatment (Week 15-18)</time_frame>
    <description>Proportion of patients achieving MRI-confirmed down-staging in T stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour regrowth</measure>
    <time_frame>Through study completion, up to 36 months post randomisation</time_frame>
    <description>Proportion of patients with local regrowth after a cCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>36 months</time_frame>
    <description>Recurrence free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colostomy</measure>
    <time_frame>Immediately after surgery / throughout study completion, up to 36 months post randomisation</time_frame>
    <description>Proportion of patients who have a permanent colostomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delivery of radical treatment</measure>
    <time_frame>End of treatment (Week 15-18)</time_frame>
    <description>Proportion of patients who proceed to surgery (or who have a complete clinical response and go onto the deferred surgery pathway).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy delivery</measure>
    <time_frame>End of treatment (Week 15-18)</time_frame>
    <description>Proportion of patients receiving at least 4 fractions of short course RT or 20 fractions of long course RT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>Proportion of patients with Grade 3-5 complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30)</measure>
    <time_frame>Baseline and months 3, 6, 12, 18, 24 and 30.</time_frame>
    <description>EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social) (higher score = better functioning), global health status (higher score=better functioning), symptom scales (fatigue, pain, nausea/vomiting) (higher score= worse symptoms), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties) (higher scores=worse difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer 29 (EORTC QLQ-CR29)</measure>
    <time_frame>Baseline and months 3, 6, 12, 18, 24 and 30.</time_frame>
    <description>All scales and single-item measurements range from 0 to 100. A higher score for a symptom scale / item indicates a higher symptomatology and problem level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Qol-5 dimensions 3 levels (EQ5D-3L)</measure>
    <time_frame>Baseline and months 3, 6, 12, 18, 24 and 30.</time_frame>
    <description>Quality of life questionnaire that measures quality of life in 5 dimensions on a 3 part scale (1=no problems, 3=extreme problems). Min score: 11111 Max score: 33333</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Rectal Adenocarcinoma</condition>
  <condition>Rectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy&#xD;
Short course radiotherapy (25Gy delivered in 5 fractions) starting on day 1&#xD;
FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy and continuing for 6 cycles in total&#xD;
Assessment of response will be at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy&#xD;
Long course chemoradiotherapy (50Gy to boost volume, 45Gy to elective volume delivered in 25 fractions) starting on day 1&#xD;
FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy for 4 cycles&#xD;
Assessment of response at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Flat dose of 1500mg delivered intravenously over 30 minutes every 4 weeks.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>MEDI 4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX</intervention_name>
    <description>Oxaliplatin 85mg/m2 delivered intravenously as per institutional standard on Day 1 of mFOLFOX6 treatment every 2 weeks.&#xD;
5-fluorouracil bolus 400mg/m2 delivered intravenously as per institutional standard on D1 of mFOLFOX6 treatment every 2 weeks.&#xD;
5-fluorouracil infusion 2400mg/m2 delivered intravenously over 46 hours continuously as per institutional standard following bolus 5-fluorouracil.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>mFOLFOX6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Short Course Radiotherapy (Arm A)</intervention_name>
    <description>25 Gray of photon radiation treatment delivered over 5 fractions.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Long course chemoradiation (Arm B)</intervention_name>
    <description>50 Gray of photon radiation treatment delivered over 25 fractions.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine is a non-cytotoxic pre-cursor of cytotoxic 5-fluorouracil and delivered in oral form. It is given concomitantly with long course radiation treatment on days of radiotherapy only. The dose is 825mg/m2 and this is delivered twice daily.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Main trial):&#xD;
&#xD;
          1. Be willing and able to provide written informed consent for the trial.&#xD;
&#xD;
          2. Willingness to comply with scheduled visits, treatment plans and laboratory tests and&#xD;
             other trial procedures including willingness to provide repeated biopsy samples of&#xD;
             tumour via flexible sigmoidoscopy.&#xD;
&#xD;
          3. Age 18 or over on the day of signing informed consent.&#xD;
&#xD;
          4. Histologically confirmed non-metastatic, locally advanced rectal adenocarcinoma deemed&#xD;
             appropriate for radical treatment.&#xD;
&#xD;
          5. Non-metastatic disease confirmed with CT of chest/abdomen and pelvis.&#xD;
&#xD;
          6. The rectal tumour must have at least one of the following high risk criteria on MRI&#xD;
             scan:&#xD;
&#xD;
             cT3b+ OR EMVI positive, OR Primary tumour or morphologically malignant lymph node at&#xD;
             2mm or less from the mesorectal fascia or beyond the mesorectal fascia OR Low rectal&#xD;
             tumour and the consensus of the multi-disciplinary meeting is that abdomino-perineal&#xD;
             excision would be required for sufficient surgical management.&#xD;
&#xD;
          7. ECOG performance status 0-1&#xD;
&#xD;
          8. No contra-indication to treatment with pelvic radiotherapy.&#xD;
&#xD;
          9. Primary disease which can be encompassed within a radical radiotherapy treatment&#xD;
             volume.&#xD;
&#xD;
         10. Adequate haematological and biochemical function&#xD;
&#xD;
        Exclusion Criteria (Main trial):&#xD;
&#xD;
          1. Patients with Dihydroppyrimidine Dehydrogenase (DPD) deficiency (any degree).&#xD;
&#xD;
          2. Unable to have MRI assessment.&#xD;
&#xD;
          3. Patient weight less than or equal to 30kg.&#xD;
&#xD;
          4. Previous pelvic radiotherapy&#xD;
&#xD;
          5. Metastatic disease defined by CT (includes resectable metastases).&#xD;
&#xD;
          6. Previous treatment with immunotherapy.&#xD;
&#xD;
          7. Previous treatment with chemotherapy for the treatment of current malignancy or&#xD;
             treatment with chemotherapy within the last 5 years for a separate malignancy (unless&#xD;
             that malignancy was treated squamous/basal cell skin cancer, treated early stage&#xD;
             cervical cancer or treated/biochemically stable, organ confined prostate cancer).&#xD;
&#xD;
          8. History of a separate malignancy in the last 5 years (other than treated&#xD;
             squamous/basal cell skin cancer, treated early stage cervical cancer or&#xD;
             treated/biochemically stable, organ confined prostate cancer).&#xD;
&#xD;
          9. Pregnant or lactating females or males unwilling to use a highly effective method of&#xD;
             contraception. Women of childbearing potential, and men with female partners of&#xD;
             childbearing potential, must agree to use adequate contraceptive measures (see section&#xD;
             9.1.12) for the duration of the study and for 6 months after the completion of study&#xD;
             treatment.&#xD;
&#xD;
         10. Major surgery within 28 days prior to trial entry&#xD;
&#xD;
         11. Prolongation of corrected QT (QTc) interval to &gt;470 msec when electrolyte balance is&#xD;
             normal.&#xD;
&#xD;
         12. If a patient has had a recent occurrence (within 3-6 months) of a major thromboembolic&#xD;
             event, such as pulmonary embolism or proximal deep vein thrombosis, they must be&#xD;
             stable on therapeutic anticoagulation. Subjects with a history of clinically&#xD;
             non-significant thromboembolic events, not requiring anticoagulation, are allowed on&#xD;
             study.&#xD;
&#xD;
         13. Active inflammatory bowel disease affecting the colon and rectum based on previous&#xD;
             endoscopy and defined as active by ongoing drug treatment.&#xD;
&#xD;
         14. Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (e.g., levothyroxine, insulin, or physiologic&#xD;
             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is&#xD;
             not considered a form of systemic treatment. Patients with diabetes type I, vitiligo,&#xD;
             psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are&#xD;
             eligible.&#xD;
&#xD;
         15. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (in dosing exceeding 10 mg daily of prednisolone equivalent) or any other form of&#xD;
             immunosuppressive therapy within 7 days prior to the first dose of trial drug.&#xD;
&#xD;
         16. Has a history of (non-infectious) interstitial pneumonia or pneumonitis that required&#xD;
             steroids or current pneumonitis.&#xD;
&#xD;
         17. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         18. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         19. Has received a live vaccine within 30 days prior to the first dose of trial drug. 21.&#xD;
             Any patients receiving treatment with brivudine, sorivudine and analogues or patients&#xD;
             who have not stopped these drugs at least 4 weeks prior to start of study treatment&#xD;
             22. Any patient with severe diarrhoea (defined as â‰¥ grade 3 diarrhoea despite maximum&#xD;
             supportive measures and exclusion of underlying infection).&#xD;
&#xD;
         20. Known hypersensitivity for any component of any study drug.&#xD;
&#xD;
         21. Administration of any investigational drug within 28 days or 5 half-lives, whichever&#xD;
             is longer, prior to receiving the first dose of trial treatment.&#xD;
&#xD;
         22. Uncontrolled Chronic Heart Failure (CHF), or history of myocardial infarction (MI),&#xD;
             unstable angina, stroke, or transient ischemia within previous 6 months.&#xD;
&#xD;
         23. Patients with known malabsorption or inability to comply with oral medication.&#xD;
&#xD;
         24. Patients with known human immunodeficiency virus (HIV1/2). This is an exclusion&#xD;
             criteria because the blood samples from these patients cannot be processed at the&#xD;
             translational laboratories linked with this trial. Screening for HIV is not required&#xD;
             for this trial.&#xD;
&#xD;
         25. Patients with known Hepatitis B or Hepatitis C. This is an exclusion criteria as the&#xD;
             blood samples from these patients cannot be processed at the translational&#xD;
             laboratories linked with this trial. Screening for hepatitis B or C is not required&#xD;
             for this trial.&#xD;
&#xD;
         26. Receiving systemic steroid therapy or any other form of immunosuppressive therapy&#xD;
             within 14 days prior to the first dose of trial treatment. Includes prior organ&#xD;
             transplantation including allogenic stem-cell transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liz-Anne Lewsley</last_name>
    <phone>01413017000</phone>
    <email>Liz-Anne.Lewsley@glasgow.ac.uk</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Research UK, Glasgow</investigator_affiliation>
    <investigator_full_name>Liz-Anne Lewsley</investigator_full_name>
    <investigator_title>Project Manager</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

